Develop therapeutics for refractory chronic cough (RCC). Focus on cough hypersensitivity indications. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
An average decline of 11% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
This company is not turning a profit, so the market is pricing its sales instead: 116,865.2× for every dollar of annual revenue.
Analysts' average target sits 0% above today's price.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: Right now the product sells for less than it costs to make; every sale deepens the loss.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
The company sells $16K a year; the problem isn’t sales — it’s costs running above that number.
There is $337.1M in the vault; even if every debt were paid off, $335.8M would remain.
A loss of $76.1M against $16K in annual sales.
The price action doesn’t yet back an upward turn. Council score: 0/10.
Right now the product sells for less than it costs to make; every sale deepens the loss. Council score: 3/10.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.